SAN FRANCISCO, Nov. 22 /PRNewswire/ -- Gentiae Clinical Research, a premier provider of centralized cardiac safety monitoring, analysis and global logistical services, announced today the addition of Rick Gallisa to its executive team, as vice president, sales and marketing.
Mr. Gallisa will be responsible for identifying, negotiating and managing business partnerships that will enhance Gentiae's offerings and market exposure, driving growth in all three segments of the company's business -- cardiovascular core laboratory services, clinical research services and technology-enabled services. Additionally, he will organize and direct Gentiae's growing sales team.
During his 16 years at Honeywell International, a Fortune 500 company, Mr. Gallisa held increasingly senior positions in sales, national accounts and general management in both the commercial and industrial markets. Most recently, he served as managing director for Honeywell's Life Sciences Global Business Unit. Prior to that, he was vice president of global sales and marketing for POMS, a wholly owned subsidiary providing enterprise software for supply chain and compliance management in life science manufacturing operations. Mr. Gallisa graduated from Ohio State University with a B.S. in marketing and an emphasis in international economics.
"Rick has a proven track record in marketing enterprise software and services to the pharmaceutical industry and a talent for building effective sales teams," said Michael Kokesh, Gentiae's president and chief executive officer. "We are forecasting an increase in sales of 250 percent for our 2005 fiscal year, following a growth in sales of over 300 percent this last fiscal year. Rick's expertise will play an integral role in helping Gentiae achieve that growth."
"The opportunity to work with a leader in service and technology innovation attracted me to Gentiae," said Mr. Gallisa. "The company's LifeSignals(TM) technology platform is a uniquely comprehensive, enterprise level solution carefully designed to meet the needs of a sophisticated and demanding customer base. I look forward to working with Michael as a member of his executive team and leading the sales effort at Gentiae."
The LifeSignals technology platform provides the most comprehensive, fully integrated suite of technology and clinical services for digital acquisition, centralized analysis, archival storage and enterprise-wide management of ECG waveforms in XML format, as well as other forms of cardiac safety data. Designed to meet emerging international regulatory requirements for assessing cardiac safety in clinical studies, the LifeSignals platform also enables clients to create a single, searchable enterprise repository of ECG data, providing immediate access to retrieve, analyze and mine datasets across multiple clinical trials.
Gentiae Clinical Research, Inc., based in San Francisco, is an internationally recognized provider of cardiovascular core laboratory services including electrocardiography (ECG), Holter, echocardiography (ECHO) and angiography. As a spin-off from the Ischemia Research and Education Foundation, Gentiae's ECG central laboratory inherits more than 17 years of experience interpreting cardiac safety data for global studies. Gentiae manages the collection, measurement, clinical interpretation, analysis, archiving and submission of digital ECG data and diagnostic images through its LifeSignals. technology platform, a customized suite of technology and clinical services designed to meet the requirements of global regulatory authorities, including the U.S. Food & Drug Administration's emerging international regulatory guidance and technical standards.
The name Gentiae, based on a Latin root, means "people of the world."
Gentiae Clinical Research, Inc.